<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109272">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920464</url>
  </required_header>
  <id_info>
    <org_study_id>116296</org_study_id>
    <nct_id>NCT01920464</nct_id>
  </id_info>
  <brief_title>Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians</brief_title>
  <acronym>flixovate HAS</acronym>
  <official_title>Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>France: GSK observational study</authority>
    <authority>France: CCTRIS, CNOM &amp; CNIL</authority>
    <authority>France: Haute Autorité de santé (HAS)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study has been request by french health authorities to evaluate the use of flixovate in
      infants and its place in the treatment pathway.

      this study has 2 main pbjectives: 1/ Evaluation of changes in the prescription share of
      Flixovate® compared to other topical corticosteroids (low, medium and high potency) in the
      population of infants aged from 3 to 12 months, from 1st January 2010 to 31st December 2012.
      2/Description of the conditions of use of Flixovate® in infants aged less than 12 months
      (infant profile, dosage form, dosage, treatment duration, prior, concomitant and subsequent
      treatments etc.).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Description of the conditions of use of Flixovate® in infants aged less than 12 months</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>data collected and analysed: Profile of prescribers (age, sex, geographic location), Profile of infants (age, age group, gender, Z-score, medical history), Conditions (diagnoses corresponding to prescriptions of Flixovate®, dosage, mean duration of treatment and duration in classes, previous treatment, concomitant medications, treatments prescribed after discontinuation of Flixovate®. (emollients and other topical steroids).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>- Evaluation of changes in the prescription share of Flixovate® compared to other topical corticosteroids (low, medium and high potency) in the population of infants aged from 3 to 12 months, from 1st January 2010 to 31st December 2012.</measure>
    <time_frame>baseline, one year, 2 years, 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>data collected and analysed: Profile of prescribers (age, gender, geographical location). Number of prescriptions of Flixovate® and other topical steroids by class, INN and brand name</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        retrospective database extraction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Analysis of changes in share of prescriptions:

          -  Infants who received at least one prescription of topical steroids between 1st
             January 2010 and 31st December 2012.

          -  Infants aged 3 to 12 months on the day of prescription of topical steroids.

        Description of the conditions of use and patient profiles:

          -  Infants who received at least one prescription of topical steroids between 1st
             January 2010 and 31st December 2012.

          -  Infants aged 3 to 12 months on the day of prescription of topical steroids.

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
